Meeting
2019 ASCO Annual Meeting
A phase II, double-blinded, randomized study using a proprietary amino acid mixture as diarrhea prevention in patients undergoing autologous stem cell transplantation (AST) for multiple myeloma (MM) and non-Hodgkin lymphoma (NHL).
Authors
Laura Luque
Entrinsic Health Solutions, Inc., Norwood, MA
Laura Luque , Robert Soiffer , Brett Glotzbecker , Haesook Kim , Zachariah Michael DeFilipp , Dorothy Mary Kate Keefe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Palliative Care and Symptom Management
Clinical Trial Registration Number
NCT02919670
Citation
J Clin Oncol 37, 2019 (suppl; abstr 11607)
DOI
10.1200/JCO.2019.37.15_suppl.11607
Abstract #
11607
Poster Bd #
299
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Phase II trial of umbilical cord blood-derived natural killer cells for multiple myeloma.
First Author: Nina Shah
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Treatment outcomes by stratifying the N-acetyl transferase 2 phenotype in pre-treated patients with advanced refractory biliary tract cancer treated with nanvuranlat, an L-type amino acid transporter inhibitor: An ad-hoc analysis of a randomized, double-blind, placebo-controlled phase 2 study.
First Author: Naohiro Okano
Poster
2023 ASCO Annual Meeting
Busulfan, melphalan, and carfilzomib (BuMelCar) conditioning for autologous stem cell transplant (ASCT) in multiple myeloma: Phase I/II data.
First Author: Joseph Allan Norton
Poster
2022 ASCO Annual Meeting
Impact of second primary malignancy post-autologous hematopoietic stem cell transplantation on outcomes of multiple myeloma: A CIBMTR analysis.
First Author: Brittany K. Ragon